Agendia

Agendia provides clinically validated genomic tests—primarily MammaPrint® and BluePrint®—that help guide personalized treatment decisions for early-stage breast cancer patients. These tests are supported by extensive clinical evidence, including prospective outcome data and inclusion in major guidelines. The company continues to innovate through partnerships, expanded market access, next-generation sequencing initiatives, and the FLEX Study—the world’s largest real-world transcriptome database focused on breast cancer. Their solutions enable faster turnaround times (<10 business days) with high success rates (>95%), supporting improved patient outcomes by minimizing over/under-treatment.